Skip to main content
AmigoFish

Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1

From BiotechTV - News · · 11 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.

Back to BiotechTV - News · Report a problem